- Home
- CASI vs NRXP Comparison
CASI vs NRXP Comparison
Compare CASI & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASI
- NRXP
- Stock Information
- Founded
- CASI 1991
- NRXP 2015
- Country
- CASI China
- NRXP United States
- Employees
- CASI N/A
- NRXP N/A
- Industry
- CASI Biotechnology: Pharmaceutical Preparations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- CASI Health Care
- NRXP Health Care
- Exchange
- CASI Nasdaq
- NRXP Nasdaq
- Market Cap
- CASI 31.0M
- NRXP 32.6M
- IPO Year
- CASI 1996
- NRXP N/A
- Fundamental
- Price
- CASI $1.89
- NRXP $2.04
- Analyst Decision
- CASI Strong Buy
- NRXP Strong Buy
- Analyst Count
- CASI 1
- NRXP 4
- Target Price
- CASI $4.00
- NRXP $28.50
- AVG Volume (30 Days)
- CASI 8.4K
- NRXP 106.0K
- Earning Date
- CASI 05-20-2025
- NRXP 05-20-2025
- Dividend Yield
- CASI N/A
- NRXP N/A
- EPS Growth
- CASI N/A
- NRXP N/A
- EPS
- CASI N/A
- NRXP N/A
- Revenue
- CASI $28,537,000.00
- NRXP N/A
- Revenue This Year
- CASI N/A
- NRXP N/A
- Revenue Next Year
- CASI N/A
- NRXP N/A
- P/E Ratio
- CASI N/A
- NRXP N/A
- Revenue Growth
- CASI N/A
- NRXP N/A
- 52 Week Low
- CASI $1.64
- NRXP $1.10
- 52 Week High
- CASI $7.67
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- CASI 44.54
- NRXP 51.01
- Support Level
- CASI $1.64
- NRXP $1.97
- Resistance Level
- CASI $1.94
- NRXP $2.14
- Average True Range (ATR)
- CASI 0.09
- NRXP 0.11
- MACD
- CASI -0.00
- NRXP 0.01
- Stochastic Oscillator
- CASI 55.77
- NRXP 62.26
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.